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ABSTRACT
RCTs would be more useful if there were more realistic expectations of them and if their pitfalls 
were better recognized. For example, and contrary to many claims in the applied literature, 
randomization does not equalize everything but the treatment across treatments and controls, it 
does not automatically deliver a precise estimate of the average treatment effect (ATE), and it 
does not relieve us of the need to think about (observed or unobserved) confounders. Estimates 
apply to the trial sample only, sometimes a convenience sample, and usually selected; 
justification is required to extend them to other groups, including any population to which the 
trial sample belongs. Demanding “external validity” is unhelpful because it expects too much of 
an RCT while undervaluing its contribution. Statistical inference on ATEs involves hazards that 
are not always recognized. RCTs do indeed require minimal assumptions and can operate with 
little prior knowledge. This is an advantage when persuading distrustful audiences, but it is a 
disadvantage for cumulative scientific progress, where prior knowledge should be built upon and 
not discarded. RCTs can play a role in building scientific knowledge and useful predictions but 
they can only do so as part of a cumulative program, combining with other methods, including 
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able	to	identify	other	quantities	of	interest.	Without	these	assumptions,	inferences	must	be	based	on	the	difference	in	the	two	means,	a	statistic	that	is	sometimes	ill-behaved,	as	we	shall	discuss	below.	This	ill-behavior	has	nothing	to	do	with	RCTs,	per	se,	but	within	RCTs,	and	their	minimal	assumptions,	we	cannot	easily	switch	from	the	mean	to	some	other	quantity	of	interest.		 Fisher	proposed	that	statistical	inference	should	be	done	using	what	has	be-come	known	as	“randomization”	inference,	a	procedure	that	is	as	non-parametric	as	the	RCT-based	estimate	of	an	ATE	itself.	To	test	the	null	hypothesis	that	𝛽( = 0	for	all	i,	note	that,	under	the	null	that	the	treatment	has	no	effect	on	any	individual,	an	estimated	nonzero	ATE	must	be	a	consequence	of	the	particular	random	allocation	that	generated	it.	By	tabulating	all	possible	combinations	of	treatments	and	controls	in	our	trial	sample,	and	the	ATE	associated	with	each,	we	can	calculate	the	exact	dis-tribution	of	the	estimated	ATE	under	the	null.	This	allows	us	to	calculate	the	proba-bility	of	calculating	an	estimate	as	large	as	our	actual	estimate	when	there	are	no	ef-fects	of	treatment.	This	randomization	test	requires	a	finite	sample,	but	it	will	work	for	any	sample	size	(see	Imbens	and	Wooldridge	(2009)	for	an	excellent	account	of	the	procedure).	Imbens	(2010)	argues	that	it	is	this	randomization	inference	plus	the	unbiasedness	of	the	ATE	that	provides	the	twin	non-parametric	pillars	that	sup-port	placing	RCTs	at	the	“very	top”	of	the	hierarchy	of	evidence.			 Randomization	inference	can	be	used	for	null	hypotheses	that	specify	that	all	of	the	treatment	effects	are	zero,	as	in	the	above	example,	but	it	cannot	be	used	to	test	the	hypothesis	that	the	average	treatment	effect	is	zero,	which	will	often	be	of	interest.	In	agricultural	trials,	and	in	medicine,	the	stronger	(sharp)	hypothesis	that	the	treatment	has	no	effect	whatever	is	often	of	interest.	In	many	economic	applica-tions	that	involve	money,	such	as	welfare	experiments	or	cost-benefit	analyses,	we	are	interested	in	whether	the	net	effect	of	the	treatment	is	positive	or	negative,	and	in	these	cases,	randomization	inference	cannot	be	used.	None	of	which	argues	against	its	wider	use	in	social	sciences	when	appropriate.		 In	cases	where	randomization	inference	cannot	be	used,	we	must	construct	tests	for	the	differences	in	two	means.	Standard	procedures	will	often	work	well,	but	there	are	two	potential	pitfalls.	One,	the	‘Fisher-Behrens	problem’,	comes	from	the	
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(1987,	1988)),	there	is	a	single	very	large	outlier.	The	authors	realize	that	the	com-parison	of	means	across	treatment	arms	is	fragile,	and,	although	they	do	not	see	their	problem	exactly	as	described	here,	they	obtain	their	preferred	estimates	using	a	structural	approach	that	is	explicitly	designed	to	model	the	skewness	of	expendi-tures.			 In	some	cases,	it	will	be	appropriate	to	deal	with	outliers	by	trimming,	trans-forming,	or	eliminating	observations	that	have	large	effects	on	the	estimates.	But	if	the	experiment	is	a	project	evaluation	designed	to	estimate	the	net	benefits	of	a	pol-icy,	the	elimination	of	genuine	outliers,	as	in	the	Rand	Health	Experiment,	will	viti-ate	the	analysis.	It	is	precisely	the	outliers	that	make	or	break	the	program.	Trans-formations,	such	as	taking	logarithms,	may	help	to	produce	symmetry,	but	they	change	the	nature	of	the	question	being	asked;	a	cost	benefit	analysis	must	be	done	in	dollars,	not	log	dollars.		 We	consider	an	example	that	illustrates	what	can	happen	in	a	realistic	but	simplified	case;	the	full	results	are	reported	in	the	Appendix.	We	imagine	a	popula-tion	of	individuals,	each	with	a	treatment	effect	𝛽( .	The	parent	population	mean	of	the	treatment	effects	is	zero,	but	there	is	a	long	tail	of	positive	values;	we	use	a	left-shifted	lognormal	distribution.	We	have	a	microfinance	trial	in	mind,	where	there	is	a	long	positive	tail	of	rare	individuals	who	can	do	amazing	things	with	credit	while	most	people	cannot	use	it	effectively.	A	trial	sample	of	2n 	individuals	is	randomly	drawn	from	the	parent	population	and	is	randomly	split	between	n	treatments	and	
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Pearl, Judea and Elias Bareinboim, 2014, “External validity: from do-calculus to trans-















Appendix:	Monte	Carlo	experiment	for	an	RCT	with	outliers	In	this	illustrative	example,	there	is	parent	population	each	member	of	which	has	his	or	her	own	treatment	effect;	these	are	continuously	distributed	with	a	shifted	lognormal	distribu-tion	with	zero	mean	so	that	the	population	ATE	is	zero.	The	individual	treatment	effects	β 	are	distributed	so	that	 β + e0.5 ∼ Λ(0,1) ,	for	standardized	lognormal	distribution	Λ. 	In	the	absence	of	treatment,	everyone	in	the	sample	records	zero,	so	the	sample	average	treat-ment	effect	in	any	one	trial	is	simply	the	mean	outcome	among	the	n	treatments.	For	values	of	n	equal	to	25,	50,	100,	200,	and	500	we	draw	from	the	parent	population	100	trial	sam-ples	each	of	size	2n;	with	five	values	of	n,	this	gives	us	500	trial	samples	in	all;	because	of	sampling	the	true	ATE’s	in	each	trial	sample	will	not	be	zero.	For	each	of	these	500	samples,	we	randomize	into	n	controls	and	n	treatments,	estimate	the	ATE	and	its	estimated	t–value	(using	the	standard	two-sample	t–value,	or	equivalently,	by	running	a	regression	with	ro-bust	t–values),	and	then	repeat	1,000	times,	so	we	have	1,000	ATE	estimates	and	t–values	for	each	of	the	500	trial	samples.	These	allow	us	to	assess	the	distribution	of	ATE	estimates	and	their	nominal	t–values	for	each	trial.		The	results	are	shown	in	Table	A1.	Each	row	corresponds	to	a	sample	size.	In	each	row,	we	show	the	results	of	100,000	individual	trials,	composed	of	1,000	replications	on	each	of	the	100	trial	(experimental)	samples.	The	columns	are	averaged	over	all	100,000	tri-als.			 	
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